Correlation Between Baseline Characteristics and Clinical Outcomes in a Large Population of Diabetes Patients Treated with Liraglutide in a Real-World Setting in Italy
- 1 March 2015
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 37 (3) , 574-584
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Differentiating among incretin therapies: a multiple-target approach to type 2 diabetesJournal of Clinical Pharmacy and Therapeutics, 2012
- Standards of Medical Care in Diabetes—2012Diabetes Care, 2011
- Glucagon-like Peptide–1 Analogues for Type 2 Diabetes MellitusDrugs, 2011
- The Role of Incretin Therapy at Different Stages of DiabetesThe Review of Diabetic Studies, 2011
- Management of type 2 diabetes: NICE guidelinesClinical Medicine, 2009
- β-Cell Failure in Diabetes and Preservation by Clinical TreatmentEndocrine Reviews, 2007
- The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitroBiochemical and Biophysical Research Communications, 2005
- Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human IsletsEndocrinology, 2003
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000